ARTHROTEC (diclofenac sodium and misoprostol) by Pfizer is sodium/misoprostol is a combination product containing diclofenac sodium, an nsaid with analgesic, anti-inflammatory and antipyretic properties, and misoprostol, a gi mucosal protective prostaglandin-1 (pge1) analog. Approved for prostaglandin e1 analog [epc], the signs, symptoms of osteoarthritis and 6 more indications. First approved in 1997.
Drug data last refreshed 13h ago · AI intelligence enriched 6d ago
ARTHROTEC is a fixed-dose oral combination of diclofenac sodium (NSAID) and misoprostol (PGE1 analog) indicated for osteoarthritis and rheumatoid arthritis in patients at high risk of NSAID-induced gastrointestinal ulcers. Diclofenac inhibits COX-1 and COX-2 to reduce pain and inflammation, while misoprostol protects the gastric mucosa by increasing bicarbonate and mucus secretion. This synergistic approach addresses both therapeutic efficacy and GI safety tolerability.
LOE-approaching product with low current spending ($0M recorded) signals reduced investment and smaller, maintenance-focused commercial teams focused on existing patient base retention.
sodium/misoprostol is a combination product containing diclofenac sodium, an NSAID with analgesic, anti-inflammatory and antipyretic properties, and misoprostol, a GI mucosal protective prostaglandin-1 (PGE1) analog. Diclofenac The mechanism of action of diclofenac, like that of other NSAIDs, is…
Worked on ARTHROTEC at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Prostaglandin E1 Analog
ARTHROTEC roles are typically structured around maintenance and managed decline, involving small, lean teams focused on brand defense against generics and payer negotiations rather than growth and innovation. Professionals on this product should expect stable but not expansive career trajectories, with emphasis on operational efficiency and cost-competitive positioning.